Capricor Faces Securities Lawsuit Over Deramiocel Data Changes
Aug 18, 2026, 8:04 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The combination of alleged misstatements, undisclosed data-plan changes, FDA concerns, and a pending lead-plaintiff deadline creates downside risk to CAPR through potential settlement costs, prolonged regulatory scrutiny, and ongoing negative sentiment. Similar biotech cases have driven headwinds when regulatory milestones collide with litigation (e.g., post-FDA setbacks followed by settlements or extended reviews).
AI summary
What happened, with direct paths to the underlying reporting
Capricor Therapeutics is named in a securities class action alleging misstatements about Deramiocel and undisclosed changes to its statistical analysis plan. The timeline spans Dec 17, 2025 to Jul 26, 2026, amid FDA briefing disclosures and a 9-3 advisory-committee vote against efficacy, triggering meaningful stock volatility. A lead-plaintiff deadline of Sept 28, 2026 heightens near-term legal risk and headlines.
Securities class-action filed against Capricor over Deramiocel data changes.
Class Period: Dec 17, 2025 to Jul 26, 2026.
FDA advisory committee vote: 9-3 against Deramiocel efficacy.
Lead plaintiff deadline: Sept 28, 2026; potential impact on CAPR.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Capricor reported that the FDA extended the PDUFA target date for Deramiocel to November 22, 2026 after submitting a major amendment with 24-month HOPE-3 data aimed at a refined u…
Capricor Therapeutics surged in premarket trading after news the FDA is willing to review new data on its experimental Duchenne muscular dystrophy therapy. The regulatory openness…
Capricor reported that the FDA advisory committee found Deramiocel's evidence insufficient for Duchenne cardiomyopathy, a non-binding result that tempers near-term approval prospe…
Capricor Therapeutics faces a securities-law investigation by Johnson Fistel amid Reuters detailing FDA concerns over deramiocel data and trial design. The disclosure triggered a…
